Companies · Pharmaceuticals

Avicanna Inc.

TORONTO · Pharmaceuticals

Diligence memoA one-page analyst read on Avicanna Inc. — recommendation, valuation, rhythm, risks.
$9.9M
Total raised · real
5
Rounds
1.9×
Latest step-up
Top 48%
Sector rank · raised
Series A
Latest stage · inferred · Wed Aug 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Avicanna Inc. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.75× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
  • Within the normal band (75% of peer median) for its niche.
At-risk
  • Last raise 3.9 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Avicanna Inc. is one of 1610 Pharmaceuticals companies tracked from TORONTO. By capital raised it ranks mid-pack (ahead of 53% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2022-08-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2020-04-20 Raised $185K (real) Modeled valuation $8.8M (est)$185K$8.8MPre-Seed2020Seed · 2020-08-18 Raised $2.1M (real) Modeled valuation $74M (est)$2.1M$74MSeed2020Series A · 2021-03-04 Raised $4.5M (real) Modeled valuation $103M (est)$4.5M$103MSeries A2021Series A · 2022-05-06 Raised $1.1M (real) Modeled valuation $15M (est)$1.1M$15MSeries A2022Series A · 2022-08-17 Raised $2.0M (real) Modeled valuation $24M (est)$2.0M$24MSeries A2022+$2.1M+$4.5M+$1.1M+$2.0MCumulative $9.9M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$185K · 2020
Seed$2.1M · 2020
Series A$4.5M · 2021
Series A extension$1.1M · 2022
Series A extension$2.0M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$24.3M
Base estimate est.
$2.3M
Conservative case
$80.9M
Upside case
$9.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $8.8M · 2020-04-202020Seed · modeled $74.2M · 2020-08-18Series A · modeled $103.2M · 2021-03-04Series A · modeled $14.9M · 2022-05-06Series A · modeled $24.3M · 2022-08-172022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
3.9 yr
Elapsed time used
3.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$4.3M/yr
Capital velocity
6.2 yr
On record since
2020
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$9.9M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.0M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$24.3M
Sector median$76.1M

Raised more than 53% of sector peers (real $). Modeled value above 31% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #39 of 64.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Hallux, Inc. · Series A Raised $20.0M · modeled $151.4M (est)Enalare Therapeutics Inc. · Series A Raised $23.5M · modeled $150.7M (est)Silver Creek Pharmaceuticals, Inc. · Series A Raised $12.6M · modeled $139.1M (est)NQ PE Project Stingray Parent, L.P. · Series A Raised $11.4M · modeled $131.6M (est)Acta Pharmaceuticals, Inc. · Series A Raised $13.4M · modeled $121.3M (est)Groff North America, LLC · Series A Raised $13.1M · modeled $105.8M (est)Hoth Therapeutics, Inc. · Series A Raised $33.7M · modeled $100.5M (est)Eyegate Pharmaceuticals Inc · Series A Raised $72.9M · modeled $92.5M (est)resistanceBio, Inc. · Series A Raised $12.8M · modeled $79.4M (est)T3D Therapeutics, Inc. · Series A Raised $30.0M · modeled $70.8M (est)Aspire BioPharma, Inc. · Series A Raised $10.0M · modeled $69.4M (est)Octagon Therapeutics, Inc. · Series A Raised $12.4M · modeled $68.2M (est)Avicanna Inc. (this company) Raised $9.9M · modeled $24.3M (est)Avicanna Inc.
CompanyStageRaised · realValue · estvs peer med.
Hallux, Inc.Series A$20.0M$151.4M4.65×
Enalare Therapeutics Inc.Series A$23.5M$150.7M4.62×
Silver Creek Pharmaceuticals, Inc.Series A$12.6M$139.1M4.27×
NQ PE Project Stingray Parent, L.P.Series A$11.4M$131.6M4.04×
Acta Pharmaceuticals, Inc.Series A$13.4M$121.3M3.72×
Groff North America, LLCSeries A$13.1M$105.8M3.25×
Hoth Therapeutics, Inc.Series A$33.7M$100.5M3.08×
Eyegate Pharmaceuticals IncSeries A$72.9M$92.5M2.84×
resistanceBio, Inc.Series A$12.8M$79.4M2.44×
T3D Therapeutics, Inc.Series A$30.0M$70.8M2.17×
Aspire BioPharma, Inc.Series A$10.0M$69.4M2.13×
Octagon Therapeutics, Inc.Series A$12.4M$68.2M2.09×
Avicanna Inc. this companySeries A$9.9M$24.3M0.75×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$185K2020-04-20$1.0M$8.8M90%
Seed$2.1M2020-08-18$10.4M$74.2M90%
Series A$4.5M2021-03-04$20.5M$103.2M90%
Series A$1.1M2022-05-06$5.0M$14.9M90%
Series A$2.0M2022-08-17$9.3M$24.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$185K2020-04-20
    • First recorded raise — entered as Pre-Seed.
    • 4 investors on this round.
  2. Seed$2.1M2020-08-18
    • Came back fast: 4 mo vs the ~13 mo sector norm.
    • Round 11.3× larger than the prior — scaling up.
    • 51 investors on this round.
  3. Series A$4.5M2021-03-04
    • Came back fast: 7 mo vs the ~13 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 2 investors on this round.
  4. Series A$1.1M2022-05-06
    • Raised 14 mo later, in step with the ~13 mo sector norm.
    • Round 4.1× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  5. Series A$2.0M2022-08-17
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 5 investors on this round.
Intelligence
2023 ~Q1
Modeled next raise · ~7mo cadence
$3.8M
Modeled next size est.range $2.5M$6.1M
1.9×
Last step-up
$4.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Benjamin Leavenworth1 other2020-04
Eileen McCormack1 other2022-05
Flavio Zaclis1 other2022-05
Amza Ali2020-04
Aras Azadian2020-04
Chandrakant Panchal2020-04
Davender Sohi2020-04
Dave Sohi2022-05
David Allan White2020-04
Dr. Assad Kazeminy2022-05
Dr. Chandrakant Panchal2022-05
Giancarlo Davila Char2020-04
Janet Gieesselman2020-04
John McVicar2022-05
Lucas Nosiglia2020-04
Setu Purohit2020-04
Registry & provenance

Avicanna Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1811059
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CURE PHARMACEUTICAL CorpPharmaceuticalsSeries A$9.9M$10.0Msame sector · same stage
Slate Medicines, Inc.PharmaceuticalsSeries A$10.0M$24.8Msame sector · same stage
60 Degrees Pharmaceuticals LLCPharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
LARASAN PHARMACEUTICAL CorpPharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
Natural Solutions Corp.PharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
Pharmaceutical Resource Technology, Inc.PharmaceuticalsSeries A$10.0M$37.4Msame sector · same stage
Invirsa, Inc.PharmaceuticalsSeries A$9.8M$9.2Msame sector · same stage
Modulo Bio, Inc.PharmaceuticalsSeries A$9.8M$25.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Avitide, Inc.PharmaceuticalsSeries A$309.7M90%
Avana Health, Inc.PharmaceuticalsSeed$6.9M86%
Aeterna Zentaris Inc.PharmaceuticalsSeries A$139.4M84%
Vireo Health, Inc.PharmaceuticalsSeries B$547.2M82%
Avstera Therapeutics Inc.BiotechnologySeries A$38.3M82%
Avicenna Biosciences, Inc.BiotechnologySeries A$31.5M81%
Pulmatrix, Inc.PharmaceuticalsSeries B$86.1M81%
Vivera Pharmaceuticals, Inc.PharmaceuticalsSeed$40.1M81%
Frequently asked
How much funding has Avicanna Inc. raised?
Avicanna Inc. has raised approximately $9.9M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Avicanna Inc.'s estimated valuation?
Provath's modeled valuation for Avicanna Inc. is approximately $24.3M (modeled range $2.3M–$80.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Avicanna Inc. at?
Avicanna Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Aug 17.
What does Avicanna Inc. do and where is it based?
Avicanna Inc. operates in the Pharmaceuticals sector, based in TORONTO.
Explore related

See where Avicanna Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Avicanna Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.